10

Oct

2017

19:00

BST

Live Stream

Protecting Patients With CAD Beyond the Stent: Highlighting the Gap Between Evidence and Clinical Practice

  • Views:

    Views Icon 2069
  • Likes:

    Heart Icon 0

Overview

                     

 

The following event is intended for healthcare professionals. If you are not a healthcare professional, please click here www.astrazeneca.com

 

This meeting has been organised and paid for by AstraZeneca, in collaboration with Radcliffe Cardiology and European Cardiology Review.

 

Location: Trinity Hall, Trinity College, Cambridge University, England, UK

 

This online meeting is designed for healthcare professionals involved the management and treatment pathway of ACS patients, from the hospital specialists, cardiology-related department including the Emergency services, as well as GP’s with a specific interest in cardiology.

This event will offer a scientific platform to review and discuss the duration of therapy to and beyond 12 months for ACS patients.

The presentations will focus on clinical trial and real-world evidence for the short and long-term benefits of DAPT following ACS and will review current guidelines. There will also be a discussion around disparities between evidence/recommendations and everyday practice worldwide. The meeting will also provide a forum for debate and to share experiences.

Performed By:

Lina Badimon

Lina Badimon

Moderated By:

Dominick J Angiolillo

Dominick J Angiolillo

Christopher B Granger

Christopher B Granger

Prof. Johanne Silvain

Prof. Johanne Silvain

Agenda

Welcome and introduction

Lina Badimon

The gap between scientific knowledge and clinical practice

Lina Badimon

Understanding the ongoing risk of ischemia to which patients are exposed

Johanne Silvain

Approaches with DAPT individually adapted for the patient; duration up to 12 months

Chris Granger

Approaches with DAPT individually adapted for the patient; duration over 12 months

Dominick Angiolillo

Main Learning Objectives

  • Raise awareness of the high and persistent continuous ischemic risk in CAD patients with previous MI (Apollo Helicon, Preclude, Prospect, Epicor, Grace, Reach, Frisc)
  • Highlight the gap between scientific evidence (randomized clinical trials, real-world evidence and guideline recommendations / review of updates) and daily practice at 12 months (therapy program of choice and duration of therapy) and beyond
  • Understand the reasons for the gap and how they can be addressed

Faculty Biographies

Lina Badimon

Lina Badimon

Prof Lina Badimon's research focuses on thrombosis and haemostasis, atherosclerosis and ischaemic heart disease. She has published more than 500 articles in highly qualified scientific journals with her work highly quoted in the scientific literature and she is an editorial board member for various international scientific journals, including European Cardiology Review.

View full profile
Dominick J Angiolillo

Dominick J Angiolillo

Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. 

In 2004, Dr Angiolillo joined the University of Florida College of Medicine – Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program. 

Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine.

View full profile
Christopher B Granger

Christopher B Granger

Christopher B Granger, MD, is an Associate Professor of Medicine in the Division of Cardiology at Duke University. He is Director of the Cardiac Care Unit and Co-director of Cardiovascular Clinical Trials at the Duke Clinical Research Institute. He is a Fellow of the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), Associate Editor of the American Heart Journal, and serves on the editorial boards of the Journal of the American College of Cardiology and the European Heart Journal. Dr Granger’s primary research interest is in the conduct and methodology of large randomized clinical trials in heart disease. He has co-authored over 200 peer-reviewed manuscripts.

View full profile
Prof. Johanne Silvain

Prof. Johanne Silvain

He is an interventional cardiologist, with experience in coronary angioplasty and OTC, and is Director of the Coronary Intensive Care Unit. He is licensed at the University of Medicine of Paris (UPMC) and is the author of over 100 publications in prestigious authoritative journals. The research interests of Dr. Silvain fall within the field of thrombosis (composition of thrombi) and antithrombotic drugs (anticoagulant and antiplatelet agents) and the related repercussions on haemorrhages and transfusions.

View full profile